Find stats on top websites
Industry Landscape
The fertility and ART industry is experiencing growth driven by increasing infertility rates, advancements in technology, and greater social acceptance of ART procedures. The market is competitive, with established players and emerging companies offering various services, from fertility treatments to genetic testing and support services. There's a growing focus on personalized care and holistic approaches, addressing both the physical and emotional aspects of fertility journeys. Regulatory landscapes and insurance coverage vary across regions, impacting accessibility and affordability.
Total Assets Under Management (AUM)
IVF Cycle Volume in United States
~400,000 IVF cycles
(12% (estimated based on various market reports) CAGR)
- Increased awareness and acceptance of ART
- Rising infertility rates
- Technological advancements in fertility treatments
Total Addressable Market
8 Billion USD
Market Growth Stage
Pace of Market Growth
Emerging Technologies
AI in Fertility
AI and machine learning are being used to improve embryo selection and predict IVF success rates, potentially enhancing treatment outcomes and personalization.
Gene Editing
CRISPR and other gene editing technologies hold promise for correcting genetic defects in embryos, reducing the risk of inherited diseases.
Blockchain
The use of blockchain technology can enhance data security and privacy in fertility treatments, ensuring the confidentiality of sensitive patient information.
Impactful Policy Frameworks
Fertility Clinic Success Rate and Certification Act of 1992
The Fertility Clinic Success Rate and Certification Act of 1992 mandates reporting of IVF success rates to the CDC and establishes standards for certification of embryo laboratories, aiming to provide consumers with accurate information.
This impacts businesses by requiring transparent pricing and potentially limiting the fees that can be charged for certain services, which may affect Big Happy Family's partnerships and charitable donations strategy.
Genetic Information Nondiscrimination Act (GINA) of 2008
The Genetic Information Nondiscrimination Act (GINA) of 2008 prohibits health insurers and employers from discriminating based on genetic information, promoting greater access to genetic testing without fear of discrimination.
This act impacts businesses by regulating the use of genetic information, influencing how genetic testing and counseling services can be marketed and offered alongside Big Happy Family's community and product support.
ASRM Guidelines on ART
The American Society for Reproductive Medicine (ASRM) provides guidelines on various aspects of ART, including ethical considerations, oocyte donation, and gestational surrogacy, influencing standards of care and patient rights.
The American Society for Reproductive Medicine (ASRM) guidelines indirectly impact Big Happy Family by shaping the ethical landscape and best practices of ART clinics, influencing consumer trust and expectations regarding treatment approaches and transparency.
Transform Your Ideas into Action in Minutes with WaxWing
Sign up now and unleash the power of AI for your business growth
